

Division of Laboratory Medicine

Immunology

Chronic lymphocytic/lymphoma panel

General information

Panel of markers used: CD3, CD5, CD19, CD23, CD79b, Kappa chains, Lambda chains, FMC7, CD38 (optional markers: CD10, CD11c, CD25, CD103).

Specimen transport: At room temperature. Samples should be received within 24 hours of collection

Repeat frequency: Post treatment monitoring, suspected relapse and MRD

Special precautions: Do not refrigerate samples

Laboratory information

Reporting units: Percentage of the population of cells of interest

Volume and sample type: 5mls EDTA blood, bone marrow or fluid samples (e.g. ascitic fluid, bronchoalveolar lavage, CSF, EBUS, fine needle aspirates or pleural fluids)

Method: Flow cytometry

Turnaround time (calendar days from sample receipt to authorised result): Median – 2

Participation in EQA Scheme: UK NEQAS Leukaemia Immunophenotyping Part 1 and 2

Clinical information

Indications for the test: Haematological malignancies involving lymphoid cells, to confirm relapse, to confirm remission

Factors affecting the test: Specimens should be ideally <24 hours old and never more than 48 hours old

(Last updated August 2022)